Peter W. Groeneveld, MD, MS; Elina L. Medvedeva, MS; Lorrie Walker, MA; et al.
free access
JAMA Cardiol. 2018;3(7):563-571. doi:10.1001/jamacardio.2018.1115
This cohort study investigates whether there are substantial differences in mortality rates for patients with ischemic heart disease and chronic heart failure who received care at Department of Veterans Affairs medical centers.
-
Editorial
In Pursuit of Better Measures of Quality of Care
Paul A. Heidenreich, MD, MS
JAMA Cardiol
Joshua D. Bundy, PhD, MPH; Katherine T. Mills, PhD, MSPH; Jing Chen, MD, MSc; et al.
free access
has audio
JAMA Cardiol. 2018;3(7):572-581. doi:10.1001/jamacardio.2018.1240
This study estimates the potential association of the 2017 and 2014 hypertension guideline treatment goals with the proportion of US adults defined as being hypertensive or recommended for antihypertensive treatment.
-
Podcast:
Association of the 2014 and 2017 Hypertension Guidelines With Cardiovascular Events and Deaths in US Adults
-
Editorial
Incremental Benefits and Harms of the 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline
Katy J. L. Bell, MBChB, MMed(Clin Epi), PhD; Jenny Doust, MBBS, PhD; Paul Glasziou, MBBS, PhD
JAMA Intern Med
-
Podcast:
Battle of the Heart Societies, Part 2: Who Is Right 鈥� the US or Europe 鈥� Regarding How to Manage Hypertension?
-
Blood Pressure Control鈥擬uch Has Been Achieved, Much Remains to Be Done
Lawrence J. Fine, MD, DrPH; David C. Goff, MD, PhD; George A. Mensah, MD
JAMA Cardiol
-
Podcast:
Association of the 2014 and 2017 Hypertension Guidelines With Cardiovascular Events and Deaths in US Adults
-
Editor's Note
The New Hypertension Guidelines: Compelling Population Benefit, Manageable Risk, and Time to Implement
Clyde W. Yancy, MD, MSc; Gregg C. Fonarow, MD
JAMA Cardiol
-
Podcast:
Association of the 2014 and 2017 Hypertension Guidelines With Cardiovascular Events and Deaths in US Adults
-
Podcast:
Battle of the Heart Societies, Part 2: Who Is Right 鈥� the US or Europe 鈥� Regarding How to Manage Hypertension?
Takeshi Fujiwara, MD, PhD; Yuichiro Yano, MD, PhD; Satoshi Hoshide, MD, PhD; et al.
free access
JAMA Cardiol. 2018;3(7):583-590. doi:10.1001/jamacardio.2018.1233
This cohort study uses participant data from the Japan Morning Surge鈥揌ome Blood Pressure study to examine the association between hypertension defined by a home blood pressure device and the risk for stroke and other adverse cardiovascular outcomes.
Neal A. Chatterjee, MD, MSc; M. Vinayaga Moorthy, PhD; Julie Pester, BA; et al.
free access
JAMA Cardiol. 2018;3(7):591-600. doi:10.1001/jamacardio.2018.1049
This cohort study provides contemporary estimates of sudden and/or arrhythmic death vs other competing causes of death in patients with coronary heart disease without severe systolic dysfunction to search for high-risk subgroups that might be targeted in future trials of prevention of sudden and/or arrhythmic death.
Alan S. Go, MD; Kristi Reynolds, PhD, MPH; Jingrong Yang, MA; et al.
open access
JAMA Cardiol. 2018;3(7):601-608. doi:10.1001/jamacardio.2018.1176
This cohort study analyzes the association between the burden of atrial fibrillation on 14-day noninvasive, continuous electrocardiographic monitoring and the rate of thromboembolism among adults with paroxysmal atrial fibrillation while not taking anticoagulation.
-
Editorial
When Low-Risk Atrial Fibrillation Is Not So Low Risk: Beast of Burden
Benjamin A. Steinberg, MD, MHS; Jonathan P. Piccini, MD, MHS
JAMA Cardiol
Steven A. Farmer, MD, PhD; Ali Moghtaderi, PhD, MBA; Samantha Schilsky, MPH; et al.
free access
JAMA Cardiol. 2018;3(7):609-618. doi:10.1001/jamacardio.2018.1360
This difference-in-differences study examines whether reducing malpractice risk is associated with clinical decisions involving coronary artery disease testing and treatment.
Stephen Burgess, PhD; Brian A. Ference, MD, MPhil, MSc; James R. Staley, PhD; et al.
open access
JAMA Cardiol. 2018;3(7):619-627. doi:10.1001/jamacardio.2018.1470
This mendelian randomization analysis estimates the magnitude of the change in plasma lipoprotein(a) levels needed to have the same evidence of an association with coronary heart disease risk as a 38.67-mg/dL change in low-density lipoprotein cholesterol level.